Seminars in thrombosis and hemostasis最新文献_第5页

The Overlooked Risk of Venous Thromboembolism in Psychiatric Patients: Epidemiology, Pathophysiology, and Implications for Clinical Care. 精神病人静脉血栓栓塞被忽视的风险：流行病学、病理生理学和临床护理的意义。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2024-12-13 DOI: 10.1055/s-0044-1800968

Giris Jacob, Yoab Ocytil, Benjamin Brenner

{"title":"The Overlooked Risk of Venous Thromboembolism in Psychiatric Patients: Epidemiology, Pathophysiology, and Implications for Clinical Care.","authors":"Giris Jacob, Yoab Ocytil, Benjamin Brenner","doi":"10.1055/s-0044-1800968","DOIUrl":"10.1055/s-0044-1800968","url":null,"abstract":"Psychiatric patients face a significantly shorter life expectancy than the general population due to a complex interplay of medical, behavioral, and social factors. Venous thromboembolism (VTE), encompassing both pulmonary embolism and deep vein thrombosis, is an underrecognized yet critical contributor to morbidity and mortality in this population. Evidence suggests a two to three times higher prevalence of VTE in psychiatric patients compared to the general population, with incidence rates up to 4.5 per 1,000 person-years. This elevated risk is attributed to a hypercoagulable-hypofibrinolytic state. It is influenced by metabolic abnormalities, pro-inflammatory pathways, antipsychotic medications, and genetic factors. Health care biases and reduced treatment compliance further exacerbate the burden. This review explores the epidemiology, pathophysiology, and mechanistic underpinnings of VTE in psychiatric populations, emphasizing the role of metabolic syndrome and antipsychotic therapy. To mitigate mortality and enhance outcomes for these high-risk individuals, it is imperative to address this issue through improved risk stratification and preventive strategies.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"430-437"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiphospholipid Antibodies in Mental Disorders. 精神疾病中的抗磷脂抗体。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2024-07-24 DOI: 10.1055/s-0044-1788696

Jean-Christophe Gris, Mathias Chéa, Sylvie Bouvier, Fabricio R Pereira

{"title":"Antiphospholipid Antibodies in Mental Disorders.","authors":"Jean-Christophe Gris, Mathias Chéa, Sylvie Bouvier, Fabricio R Pereira","doi":"10.1055/s-0044-1788696","DOIUrl":"10.1055/s-0044-1788696","url":null,"abstract":"Thrombotic events striking the central nervous system are clinical criteria for the antiphospholipid syndrome (APS). Besides these, neuropsychiatric non-APS criteria manifestations are increasingly described in patients with persistently positive antiphospholipid antibodies (aPL). Among these are psychiatric manifestations. Animal models mainly describe hyperactive behavior and anxiety associated with hippocampal abnormalities. Cases of associations with psychosis, mood disorders, bipolarity, anxiety, obsessive-compulsive behavior, and depression have been reported but are still rare. Systematic human clinical association studies are concordant with a risk of psychosis, depression (simple to major), and anxiety disorders, but these are limited and of inconstant methodological quality. Brain imaging in patients, also insufficiently investigated, shows early signs of hypoperfusion and of subtle diffuse white matter changes compatible with an alteration of the axonal structure and changes in the myelin sheath. Direct interactions of aPL with the brain cells, both on cell lines and on animal and human brain biopsies, targeting both glial cells, astrocytes, and neurons, can be demonstrated. These clusters of arguments make the association between psychiatric diseases and aPL increasingly plausible. However, a considerable amount of clinical research must still be performed in accordance with the highest standards of methodological quality. The therapeutic management of this association, in terms of both prevention and cure, currently remains unresolved.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"448-456"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heparin and Posttraumatic Stress Disorder. 肝素与创伤后应激障碍。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2024-07-24 DOI: 10.1055/s-0044-1788697

Giuseppe Lippi, Emmanuel J Favaloro

引用次数: 0

Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review. 抗血小板因子4抗体介导的疾病：最新的叙事回顾。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2025-01-30 DOI: 10.1055/a-2528-5425

Angela Napolitano, Luca Spiezia, Marta Biolo, Claudia Maria Radu, Serena Toffanin, Elena Campello, Paolo Simioni

{"title":"Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review.","authors":"Angela Napolitano, Luca Spiezia, Marta Biolo, Claudia Maria Radu, Serena Toffanin, Elena Campello, Paolo Simioni","doi":"10.1055/a-2528-5425","DOIUrl":"10.1055/a-2528-5425","url":null,"abstract":"Anti-platelet factor 4 (PF4) antibody-mediated disorders are a heterogeneous group of diseases characterized by the presence of highly pathogenic immunoglobulins G directed against PF4 and/or PF4/heparin complexes. These antibodies are able to activate platelets, neutrophils, and monocytes, thus resulting in thrombocytopenia and a hypercoagulable state. Five different forms of anti-PF4 antibody-mediated disorders have been identified: (1) classic heparin-induced thrombocytopenia (HIT) mediated by heparin and certain polyanionic drugs; (2) autoimmune HIT characterized by the presence of anti-PFA/polyanion antibodies that can strongly activate platelets even in the absence of heparin; (3) spontaneous HIT characterized by thrombocytopenia and thrombosis without proximate exposure to heparin, with two subtypes: (a) post-total knee arthroplasty and cardiac surgery using cardiopulmonary bypass or extracorporeal membrane oxygenation and (b) postinfections; (4) vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by thrombocytopenia, arterial and venous thrombosis, or secondary hemorrhage after receiving adenoviral vector vaccines for coronavirus disease 2019; (5) VITT-like disorders triggered by adenoviral infections. Although extremely rare and largely unknown, there has been growing interest in the VITT syndrome in recent years due to its clinical relevance. Timely detection of these antibodies is crucial for the diagnosis and treatment of anti-PF4 antibody-mediated disorders, via anti-PF4 antibody immunoassays using several antibody capture systems (e.g., enzyme-linked immunosorbent assay-based, particle gel, turbidimetry) and functional assays (e.g., serotonin release assay or heparin-induced platelet activation). We aimed to present the latest on laboratory findings, clinical characteristics, and therapeutic approaches for anti-PF4 antibody-mediated disorders.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"578-593"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review. 口服抗xa抑制剂在FIX p.（Ala37Thr）前肽变异致华法林过敏的人工机械主动脉瓣中的应用：病例报告及文献复习

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2025-02-27 DOI: 10.1055/a-2546-7180

Antonella Tufano, Carmine Fierarossa, Ferdinando Cirillo, Ciro Miele, Filomena Capasso, Cristina Mazzaccara, Lucia Micale, Gennaro Vecchione, Marco Castori, Ignazio Frangipane, Luca Mocerino, Ernesto Cimino, Matteo Di Minno

{"title":"Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review.","authors":"Antonella Tufano, Carmine Fierarossa, Ferdinando Cirillo, Ciro Miele, Filomena Capasso, Cristina Mazzaccara, Lucia Micale, Gennaro Vecchione, Marco Castori, Ignazio Frangipane, Luca Mocerino, Ernesto Cimino, Matteo Di Minno","doi":"10.1055/a-2546-7180","DOIUrl":"10.1055/a-2546-7180","url":null,"abstract":"Bleeding is the most common side effect during treatment with vitamin K antagonists (VKAs). Sometimes, VKA use causes bleeding episodes due to rare variants in the factor IX (FIX) propeptide that modify the affinity of FIX propeptide to the binding of γ-glutamyl carboxylase. We report on a 51-year-old patient who presented with recurrent spontaneous and severe intramuscular and cutaneous bleedings during VKA (warfarin) treatment for the presence of a prosthetic mechanical aortic valve. Laboratory evaluation revealed INR within the therapeutic range with markedly prolonged aPTT and a large reduction of FIX levels. Laboratory parameters significantly improved when warfarin was switched with low-molecular-weight heparin. Next-generation sequencing analysis revealed the variant p.(Ala37Thr) in the F9 gene, which has been previously associated with VKA sensitivity. As an alternative to warfarin, apixaban 5 mg twice daily and aspirin 100 mg daily were started, with no thrombosis or recurrence of hemorrhage and normalization of INR, aPTT, and FIX levels, at 12-month follow-up. We also performed a literature search across PubMed and Scopus, until January 2025. The analysis evidenced five case reports and two case series. The mechanisms of this rare VKA hypersensitivity have also been reviewed. In conclusion, while VKA hypersensitivity is a rare phenomenon, awareness of this complication and the current accessibility to molecular testing make it important to identify patients at risk. The efficacy/safety of direct thrombin or factor Xa inhibitors in patients with a mechanical heart valve and VKA hypersensitivity due to the F9 p.(Ala37Thr) variant deserves more attention and further investigation.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"594-599"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alterations in the Blood-Brain Barrier in Mood Disorders and Neurodegenerative Diseases. 情绪障碍和神经退行性疾病的血脑屏障改变。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2025-03-09 DOI: 10.1055/s-0045-1804893

Ismael Conejero, Mathias Chea, Philippe Courtet, Sylvie Bouvier, Fabricio Pereira

{"title":"Alterations in the Blood-Brain Barrier in Mood Disorders and Neurodegenerative Diseases.","authors":"Ismael Conejero, Mathias Chea, Philippe Courtet, Sylvie Bouvier, Fabricio Pereira","doi":"10.1055/s-0045-1804893","DOIUrl":"10.1055/s-0045-1804893","url":null,"abstract":"Depressive disorders and suicidal behaviors represent major causes of health loss. Modifications of brain microvasculature, and specifically alterations of the blood-brain barrier have been supposed to participate in the vulnerability to those disorders along with cognitive impairment, especially in the older adults. In this article, we addressed evidence linking blood-brain barrier impairments with mood disorders and suicide. Secondly, we investigated their relationship with depression in old age, and with neurodegenerative processes. Particular attention was drawn toward the potential interactions between the coagulation processes and the blood-brain barrier dysfunctions, as innovative treatment strategies may emerge from research in those fields. Overall, the studies reviewed highlight the implication of multiple dysfunctions of the blood-brain barrier in mood disorders and suicide. Impairments of the blood-brain barrier show relationships with altered expression of endothelial cell junction proteins. These modifications also implicate receptors of the extracellular matrix, the vascular endothelial growth factor, changes in perivascular astrocytes, and has links with local and systemic inflammatory processes. Dysfunctions of the blood-brain barrier underly chronic stress and participate in psychiatric diathesis in old age. In addition, we outline that coagulation processes are likely to interact with the blood-brain barrier and further contribute to neurodegenerative disorders. In conclusion, new pathophysiological models offer perspectives toward detecting new biomarkers in mood disorders and suicide. In parallel, these models open avenues for developing innovative therapeutic agents, although further considering their potential risks and eventual benefits is needed.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"457-464"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2025 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. 2025 Eberhard F. Mammen奖公告：第一部分-最受欢迎的文章。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2025-03-25 DOI: 10.1055/s-0045-1806855

Emmanuel J Favaloro

引用次数: 0

Stress and Pregnancy Outcomes: A Review of the Literature. 压力与妊娠结果：文献综述。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2024-11-04 DOI: 10.1055/s-0044-1792002

Shayna Miodownik, Eyal Sheiner

引用次数: 0

Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura. 免疫性血栓性血小板减少性紫癜的定制治疗。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2024-10-17 DOI: 10.1055/s-0044-1791780

Gennadiy M Galstyan, Elizaveta Klebanova, Svetlana Mamleeva, Zalina Fidarova, Michail Drokov, Dmitriy Bessmertniy

引用次数: 0

2024 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. 2024年Eberhard F. Mammen奖公告：第二部分-青年研究者奖。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-01 Epub Date: 2025-04-16 DOI: 10.1055/s-0045-1807739

Emmanuel J Favaloro

引用次数: 0